Developer docs
API playgroundTry for free, no card

Search company profiles

Know Labs

Full company profile

uuid00bzpt5

Namestring
Know Labs
Legal namestring
Know Labs, Inc.
Websiteurl
knowlabs.co
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Know Labs is a Seattle-based medical technology company developing a proprietary non-invasive diagnostic platform based on Radio Frequency Dielectric Spectroscopy (Bio-RFID). The platform rapidly scans a wide range of RF frequencies (300 MHz to 4,400 MHz), recording voltage values across over 30,000 frequency/parameter combinations and collecting roughly 1.5 million data points per hour. These signals are processed by trade-secret machine learning algorithms, including a peer-reviewed LightGBM model, to quantify blood glucose and other analytes without needles, inserted transmitters, or disposable test strips. The flagship consumer product is the KnowU, a wearable continuous glucose monitor with a rechargeable battery designed to last years, paired with the GlucoseDashboard companion mobile application on iOS and Android. Know Labs complements its hardware roadmap with the Know Labs Technology Licensing (KTL) program, which licenses the underlying RFDS platform, SDKs, prototyping tools, and customizable AI models to enterprise partners across healthcare, industrial diagnostics, automotive, and consumer electronics.

The company's go-to-market strategy is product-led and follows two tracks: (1) direct-to-consumer distribution of the KnowU device via a companion mobile app following FDA clearance, with the company claiming pricing 3x-5x below incumbent CGM options, and (2) enterprise licensing through KTL enabling OEMs and partners to embed the RFDS technology across diverse form factors. Clinical validation has been conducted in collaboration with the Mayo Clinic and published in peer-reviewed venues including IEEE Sensors Journal and Diabetes Technology & Therapeutics. The product roadmap remains gated by FDA clearance, and the company has not yet generated commercial product revenue.

In August 2025, Know Labs underwent a fundamental strategic shift when Goldeneye 1995, LLC (an affiliate of Greg Kidd) acquired a controlling interest by contributing 1,000 Bitcoin and $15 million in cash for 357.8 million new common shares, valuing the company at approximately $125 million. Greg Kidd was appointed CEO and Chairman, the corporate name was changed to USBC, Inc., and the NYSE American ticker changed from KNW to USBC. The company now operates a dual-track strategy: a digital asset/fintech arm centered on the USBC token and a Bitcoin yield-generation treasury strategy, alongside a diagnostic research division under founder Ron Erickson pursuing non-invasive medical technology development. Know Labs is publicly listed (NYSE American: USBC, formerly KNW), holds 270+ patents issued, pending, or in-process worldwide, and employs between 11 and 50 people.

Short descriptiontext

Know Labs is a Seattle-based medical technology company developing the KnowU, a non-invasive wearable continuous glucose monitor built on proprietary RF Dielectric Spectroscopy (Bio-RFID) and AI, pursuing FDA clearance for direct-to-consumer use and licensing its sensing platform to enterprise partners via the KTL program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive glucose monitoring, continuous glucose monitor, medical diagnostic devices, RF spectroscopy sensors, wearable health technology
Industry3 codes
PRIMARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Continuous Glucose Monitoring Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Device Sales (KnowU)
TypeHardware Sales
Description

Sale of the KnowU non-invasive wearable continuous glucose monitor directly to consumers. The device is designed to last years and have a rechargeable battery, eliminating the need for costly disposables, making it a one-time hardware purchase with potential companion app subscription.

knowlabs.co
2Companion Mobile App Subscription
TypeSubscription Recurring
Description

The KnowU connects with a companion mobile app via Bluetooth providing real-time glucose monitoring and trend data, likely monetized through a recurring app subscription.

knowlabs.co
3KTL IP and Technology Licensing
TypeLicensing Royalties
Description

Know Labs Technology Licensing (KTL) program licenses the company's RFDS technology, patents, SDKs, and tools to third parties across healthcare, industrial diagnostics, automotive, and consumer electronics. Revenue is generated through licensing fees, SDK access fees, wet lab services, and phase-based engagement payments.

knowlabs.co
4Digital Asset / Fintech (Post-Acquisition)
TypeData Monetisation
Description

Following the August 2025 acquisition by Greg Kidd/Goldeneye 1995, LLC, the company transitioned to include digital asset and fintech operations centered on the USBC token — a U.S.-dollar denominated digital token leveraging blockchain and digital identity technology that earns high-yield rewards. The company also retains a non-invasive diagnostic R&D division under founder Ron Erickson.

knowlabs.co
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1KnowU Device — Not yet priced; company claims 3x-5x lower cost than current CGM options
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing disclosed. The company states KnowU will last for years, has a rechargeable battery, and eliminates costly disposables (test strips, lancets). Affordability is a core value proposition.

knowlabs.co
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1KnowU
Description

Non-invasive, wearable continuous blood glucose monitor designed to improve how people with diabetes and pre-diabetes manage their conditions.

knowlabs.co
+2 more records
Core offering1 text field

Know Labs develops proprietary non-invasive diagnostic hardware and software using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules such as blood glucose without needles, inserted transmitters, or disposables. Its flagship product is the KnowU, a wearable continuous glucose monitor paired with a companion mobile app, alongside the KTL technology licensing program that offers its RFDS platform, SDKs, and IP to enterprise partners across healthcare, industrial, automotive, and consumer electronics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MARD of 12.7% in normoglycemic range and 14.0% in hyperglycemic range, validated via LightGBM AI model on 1,555 observations in peer-reviewed IEEE Sensors Journal study.
+3 more records
Product overview1 text field

Know Labs offers a proprietary non-invasive medical diagnostic technology platform using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules without needles or invasive transmitters. The core product is the KnowU, a wearable continuous glucose monitor (CGM) targeting the 2 billion people with diabetes and pre-diabetes. KnowU is a form-factor agnostic platform that can be integrated into wearable, mobile, or bench-top devices, featuring 3x-5x lower cost than current options and no disposables. The portfolio includes the companion GlucoseDashboard mobile app for iOS/Android, the Know Labs Technology Licensing (KTL) platform for third-party access to SDKs and IP licensing, and specialized data collection tools (Voltmeter, Carousel) for research applications.

Product and service5 records
1KnowU
CategoryWearable Medical Device
Description

Non-invasive wearable continuous glucose monitor using proprietary RF Dielectric Spectroscopy (Bio-RFID) technology. Worn with adhesive or strap on wrist/forearm, featuring rechargeable battery (24-hour continuous use), 256MB flash storage, BLE/Wi-Fi/USB-C connectivity, no disposables required, and designed to last for years. Pursuing FDA clearance.

2GlucoseDashboard Mobile App
CategoryCompanion Software Application
Description

Companion mobile application for the KnowU device that provides real-time blood glucose monitoring, trend visualization, and advanced research capabilities. Connects via BLE and WiFi.

3Know Labs Technology Licensing (KTL)
CategoryTechnology Licensing Platform
Description

Licensing platform enabling partners to access RFDS technology, SDKs, wet lab support, prototyping tools, white-label mobile apps, and customizable AI/ML models. Backed by over 330 patents globally covering 100+ applications, with a phase-based engagement model.

4KTL Data Collection Tools (Voltmeter, Carousel)
CategoryR&D Tools
Description

Research and development tools including 'Voltmeter' for data collection and 'Carousel' for high-volume testing of up to 12 samples simultaneously. Supports wet lab experiments for solids, liquids, and RF-related testing including depth, power, dielectrics, and material analysis.

5Portable Research System (Gen 1 Prototype)
CategoryResearch Instrument
Description

Portable research-grade RF sensor system featuring 256MB flash storage (40 hours offline research data), ultra-low power processor with onboard ML, BLE/WiFi/USB-C connectivity, and custom firmware. Distributed to clinical trial partners and research institutions.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-05
Description

Know Labs joined the Industrial Participant Program of the Wyss Institute at Harvard University in June 2024. This program provides access to cutting-edge research infrastructure and collaboration opportunities in biologically inspired engineering, supporting the company's non-invasive diagnostic technology development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-21
Description

Collaborative proof-of-principle study conducted with Mayo Clinic, demonstrating the accuracy of Know Labs' non-invasive Bio-RFID technology in quantifying different analytes in vitro. Results were peer-reviewed and published in the Sensors Journal and presented at the American Physiological Society 2023 Summit. This collaboration validated the foundational technology.

3KTL Licensee Partners (Unnamed)
Strategic tierCoreTypeTechnology or Integration
Description

Unnamed industry partners across healthcare, industrial diagnostics, automotive, and consumer electronics engaging with the Know Labs Technology Licensing (KTL) platform to access RFDS technology, SDKs, wet lab support, and white-label solutions.

knowlabs.co
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading continuous glucose monitor manufacturer (G6/G7), directly comparable to KnowU as a CGM addressing the same patient population with overlapping claims on accuracy and convenience. Dexcom is the accuracy benchmark against which Know Labs benchmarks its MARD.

TypeEmerging player
Description

Early-stage company developing a non-invasive blood glucose monitor using electromagnetic/dielectric spectroscopy. Comparable to Know Labs' Bio-RFID approach in trying to deliver needle-free glucose monitoring, but at an earlier commercialization stage.

TypeDirect peer
Description

Developer of the Eversense implantable long-term CGM, the only peer attempting a fundamentally different sensing modality (fluorescence-based) for continuous glucose. Comparable to KnowU as a non-needle-free-disposables challenger CGM pursuing differentiated patient convenience claims.

TypeBroad incumbent
Description

OneTouch blood glucose monitoring brand competing in BGM; comparable to KnowU's first-generation consumer monitoring ambition but with a legacy strip-based model that KnowU's disposable-free economics could undercut.

TypeDirect peer
Description

Abbott's FreeStyle Libre is the leading factory-calibrated flash CGM with a global installed base; comparable to KnowU in core analyte (interstitial glucose) but invasive via filament. Represents the dominant incumbent KnowU would seek to disrupt with a non-invasive modality.

TypeEmerging player
Description

Developer of a minimally invasive intradermal CGM patch focused on improving affordability and form-factor. Partially overlaps with KnowU around accessibility and wearability claims, though Biolinq retains a microneedle array.

TypeBroad incumbent
Description

Markets the CONTOUR blood glucose meter line globally, competing in patient-facing glucose monitoring. Comparable as a broader incumbent in adjacent BGM segments and a potential partner or competitor for KnowU in primary-care distribution.

TypeBroad incumbent
Description

Offers Guardian Connect CGM integrated with insulin pump ecosystems for Type 1 diabetes management. A broader incumbent across diabetes hardware, supplies, and software, with overlapping CGM capability but a much wider portfolio.

TypeBroad incumbent
Description

Long-established player offering Accu-Chek blood glucose meters, insulin delivery, and digital diabetes management. Comparable as a broad incumbent in glucose monitoring across BGM and adjacent software, even though it does not compete directly in CGM hardware.

TypeEmerging player
Description

Building a non-invasive continuous glucose monitor using radio frequency technology in a wrist-worn form factor (Evie Ring). Closest emerging non-invasive CGM competitor to KnowU, pursuing many of the same over-the-counter and consumer-health use cases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Know Labs

Continuous Glucose Monitoring Devicesknowlabs.co

Know Labs is a Seattle-based medical technology company developing the KnowU, a non-invasive wearable continuous glucose monitor built on proprietary RF Dielectric Spectroscopy (Bio-RFID) and AI, pursuing FDA clearance for direct-to-consumer use and licensing its sensing platform to enterprise partners via the KTL program.

What Know Labs does

Know Labs is a Seattle-based medical technology company developing a proprietary non-invasive diagnostic platform based on Radio Frequency Dielectric Spectroscopy (Bio-RFID). The platform rapidly scans a wide range of RF frequencies (300 MHz to 4,400 MHz), recording voltage values across over 30,000 frequency/parameter combinations and collecting roughly 1.5 million data points per hour. These signals are processed by trade-secret machine learning algorithms, including a peer-reviewed LightGBM model, to quantify blood glucose and other analytes without needles, inserted transmitters, or disposable test strips. The flagship consumer product is the KnowU, a wearable continuous glucose monitor with a rechargeable battery designed to last years, paired with the GlucoseDashboard companion mobile application on iOS and Android. Know Labs complements its hardware roadmap with the Know Labs Technology Licensing (KTL) program, which licenses the underlying RFDS platform, SDKs, prototyping tools, and customizable AI models to enterprise partners across healthcare, industrial diagnostics, automotive, and consumer electronics.

The company's go-to-market strategy is product-led and follows two tracks: (1) direct-to-consumer distribution of the KnowU device via a companion mobile app following FDA clearance, with the company claiming pricing 3x-5x below incumbent CGM options, and (2) enterprise licensing through KTL enabling OEMs and partners to embed the RFDS technology across diverse form factors. Clinical validation has been conducted in collaboration with the Mayo Clinic and published in peer-reviewed venues including IEEE Sensors Journal and Diabetes Technology & Therapeutics. The product roadmap remains gated by FDA clearance, and the company has not yet generated commercial product revenue.

In August 2025, Know Labs underwent a fundamental strategic shift when Goldeneye 1995, LLC (an affiliate of Greg Kidd) acquired a controlling interest by contributing 1,000 Bitcoin and $15 million in cash for 357.8 million new common shares, valuing the company at approximately $125 million. Greg Kidd was appointed CEO and Chairman, the corporate name was changed to USBC, Inc., and the NYSE American ticker changed from KNW to USBC. The company now operates a dual-track strategy: a digital asset/fintech arm centered on the USBC token and a Bitcoin yield-generation treasury strategy, alongside a diagnostic research division under founder Ron Erickson pursuing non-invasive medical technology development. Know Labs is publicly listed (NYSE American: USBC, formerly KNW), holds 270+ patents issued, pending, or in-process worldwide, and employs between 11 and 50 people.

Know Labs firmographics

Firmographics
Name
Know Labs
Legal name
Know Labs, Inc.
Website
https://knowlabs.co
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Know Labs is a Seattle-based medical technology company developing the KnowU, a non-invasive wearable continuous glucose monitor built on proprietary RF Dielectric Spectroscopy (Bio-RFID) and AI, pursuing FDA clearance for direct-to-consumer use and licensing its sensing platform to enterprise partners via the KTL program.
Ownership category
akta.pro rank

Know Labs industry classification

Industry
Product category
Continuous Glucose Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Non-invasive glucose monitoring
  • Continuous glucose monitor
  • Medical diagnostic devices
  • RF spectroscopy sensors
  • Wearable health technology

Where Know Labs is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Know Labs business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Hardware Device Sales (KnowU): Sale of the KnowU non-invasive wearable continuous glucose monitor directly to consumers. The device is designed to last years and have a rechargeable battery, eliminating the need for costly disposables, making it a one-time hardware purchase with potential companion app subscription.
  2. Companion Mobile App Subscription: The KnowU connects with a companion mobile app via Bluetooth providing real-time glucose monitoring and trend data, likely monetized through a recurring app subscription.
  3. KTL IP and Technology Licensing: Know Labs Technology Licensing (KTL) program licenses the company's RFDS technology, patents, SDKs, and tools to third parties across healthcare, industrial diagnostics, automotive, and consumer electronics. Revenue is generated through licensing fees, SDK access fees, wet lab services, and phase-based engagement payments.
  4. Digital Asset / Fintech (Post-Acquisition): Following the August 2025 acquisition by Greg Kidd/Goldeneye 1995, LLC, the company transitioned to include digital asset and fintech operations centered on the USBC token — a U.S.-dollar denominated digital token leveraging blockchain and digital identity technology that earns high-yield rewards. The company also retains a non-invasive diagnostic R&D division under founder Ron Erickson.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractKnowU Device — Not yet priced; company claims 3x-5x lower cost than current CGM options

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Know Labs product offering

Product offering

Core offering

Know Labs develops proprietary non-invasive diagnostic hardware and software using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules such as blood glucose without needles, inserted transmitters, or disposables. Its flagship product is the KnowU, a wearable continuous glucose monitor paired with a companion mobile app, alongside the KTL technology licensing program that offers its RFDS platform, SDKs, and IP to enterprise partners across healthcare, industrial, automotive, and consumer electronics.

Product overview

Know Labs offers a proprietary non-invasive medical diagnostic technology platform using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules without needles or invasive transmitters. The core product is the KnowU, a wearable continuous glucose monitor (CGM) targeting the 2 billion people with diabetes and pre-diabetes. KnowU is a form-factor agnostic platform that can be integrated into wearable, mobile, or bench-top devices, featuring 3x-5x lower cost than current options and no disposables. The portfolio includes the companion GlucoseDashboard mobile app for iOS/Android, the Know Labs Technology Licensing (KTL) platform for third-party access to SDKs and IP licensing, and specialized data collection tools (Voltmeter, Carousel) for research applications.

Differentiator

Problem solved

Functional benefit

Brands

  • KnowU: Non-invasive, wearable continuous blood glucose monitor designed to improve how people with diabetes and pre-diabetes manage their conditions.
  • Know Labs Technology Licensing (KTL)
  • Bio-RFID

Products and services

  • KnowU Non-invasive wearable continuous glucose monitor using proprietary RF Dielectric Spectroscopy (Bio-RFID) technology. Worn with adhesive or strap on wrist/forearm, featuring rechargeable battery (24-hour continuous use), 256MB flash storage, BLE/Wi-Fi/USB-C connectivity, no disposables required, and designed to last for years. Pursuing FDA clearance.
  • GlucoseDashboard Mobile App Companion mobile application for the KnowU device that provides real-time blood glucose monitoring, trend visualization, and advanced research capabilities. Connects via BLE and WiFi.
  • Know Labs Technology Licensing (KTL) Licensing platform enabling partners to access RFDS technology, SDKs, wet lab support, prototyping tools, white-label mobile apps, and customizable AI/ML models. Backed by over 330 patents globally covering 100+ applications, with a phase-based engagement model.
  • KTL Data Collection Tools (Voltmeter, Carousel) Research and development tools including 'Voltmeter' for data collection and 'Carousel' for high-volume testing of up to 12 samples simultaneously. Supports wet lab experiments for solids, liquids, and RF-related testing including depth, power, dielectrics, and material analysis.
  • Portable Research System (Gen 1 Prototype) Portable research-grade RF sensor system featuring 256MB flash storage (40 hours offline research data), ultra-low power processor with onboard ML, BLE/WiFi/USB-C connectivity, and custom firmware. Distributed to clinical trial partners and research institutions.

Quantifiable outcome

  • MARD of 12.7% in normoglycemic range and 14.0% in hyperglycemic range, validated via LightGBM AI model on 1,555 observations in peer-reviewed IEEE Sensors Journal study.
  • +3 more outcomes

Companies that use Know Labs

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Know Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Know Labs partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Wyss Institute for Biologically Inspired Engineering at Harvard UniversitycoreStrategic or Co-development Partner · 5 June 2024Know Labs joined the Industrial Participant Program of the Wyss Institute at Harvard University in June 2024. This program provides access to cutting-edge research infrastructure and collaboration opportunities in biologically inspired engineering, supporting the company's non-invasive diagnostic technology development.
  • Mayo CliniccoreStrategic or Co-development Partner · 21 April 2023Collaborative proof-of-principle study conducted with Mayo Clinic, demonstrating the accuracy of Know Labs' non-invasive Bio-RFID technology in quantifying different analytes in vitro. Results were peer-reviewed and published in the Sensors Journal and presented at the American Physiological Society 2023 Summit. This collaboration validated the foundational technology.
  • KTL Licensee Partners (Unnamed)coreTechnology or IntegrationUnnamed industry partners across healthcare, industrial diagnostics, automotive, and consumer electronics engaging with the Know Labs Technology Licensing (KTL) platform to access RFDS technology, SDKs, wet lab support, and white-label solutions.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Know Labs competitors and assessment

Company assessment

Direct peers

  • Dexcom: Market-leading continuous glucose monitor manufacturer (G6/G7), directly comparable to KnowU as a CGM addressing the same patient population with overlapping claims on accuracy and convenience. Dexcom is the accuracy benchmark against which Know Labs benchmarks its MARD.
  • Senseonics Holdings: Developer of the Eversense implantable long-term CGM, the only peer attempting a fundamentally different sensing modality (fluorescence-based) for continuous glucose. Comparable to KnowU as a non-needle-free-disposables challenger CGM pursuing differentiated patient convenience claims.
  • Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the leading factory-calibrated flash CGM with a global installed base; comparable to KnowU in core analyte (interstitial glucose) but invasive via filament. Represents the dominant incumbent KnowU would seek to disrupt with a non-invasive modality.

Emerging players

  • Alertgy: Early-stage company developing a non-invasive blood glucose monitor using electromagnetic/dielectric spectroscopy. Comparable to Know Labs' Bio-RFID approach in trying to deliver needle-free glucose monitoring, but at an earlier commercialization stage.
  • Biolinq: Developer of a minimally invasive intradermal CGM patch focused on improving affordability and form-factor. Partially overlaps with KnowU around accessibility and wearability claims, though Biolinq retains a microneedle array.
  • Movano Health: Building a non-invasive continuous glucose monitor using radio frequency technology in a wrist-worn form factor (Evie Ring). Closest emerging non-invasive CGM competitor to KnowU, pursuing many of the same over-the-counter and consumer-health use cases.

Broad incumbents

  • LifeScan (OneTouch): OneTouch blood glucose monitoring brand competing in BGM; comparable to KnowU's first-generation consumer monitoring ambition but with a legacy strip-based model that KnowU's disposable-free economics could undercut.
  • Ascensia Diabetes Care: Markets the CONTOUR blood glucose meter line globally, competing in patient-facing glucose monitoring. Comparable as a broader incumbent in adjacent BGM segments and a potential partner or competitor for KnowU in primary-care distribution.
  • Medtronic Diabetes: Offers Guardian Connect CGM integrated with insulin pump ecosystems for Type 1 diabetes management. A broader incumbent across diabetes hardware, supplies, and software, with overlapping CGM capability but a much wider portfolio.
  • Roche Diabetes Care: Long-established player offering Accu-Chek blood glucose meters, insulin delivery, and digital diabetes management. Comparable as a broad incumbent in glucose monitoring across BGM and adjacent software, even though it does not compete directly in CGM hardware.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Know Labs social profiles

Digital presence

Know Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Know Labs leadership team

Management profile

Number of profiles

Profiles6 records

Know Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Know Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Know Labs

What does Know Labs do?

Know Labs develops proprietary non-invasive diagnostic hardware and software using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules such as blood glucose without needles, inserted transmitters, or disposables. Its flagship product is the KnowU, a wearable continuous glucose monitor paired with a companion mobile app, alongside the KTL technology licensing program that offers its RFDS platform, SDKs, and IP to enterprise partners across healthcare, industrial, automotive, and consumer electronics.

Is Know Labs a public or private company?

Know Labs is a public company. It is classified as public and is currently operating.

When was Know Labs founded?

Know Labs was founded in 2003. It employs 11 to 50 people.

Where is Know Labs based?

Know Labs is headquartered in Seattle, United States, in the North America region.

How does Know Labs make money?

Four revenue lines are on record. Hardware Device Sales (KnowU) is the primary driver. The others are companion Mobile App Subscription, KTL IP and Technology Licensing and digital Asset / Fintech (Post-Acquisition).

Who are Know Labs's main competitors?

Direct peers on record are Dexcom, Senseonics Holdings and Abbott Diabetes Care (FreeStyle Libre). Emerging players are Alertgy, Biolinq and Movano Health. Broad incumbents are LifeScan (OneTouch), Ascensia Diabetes Care, Medtronic Diabetes and Roche Diabetes Care.

Does Know Labs have an API?

No public API is recorded for Know Labs.

What industry is Know Labs in?

Know Labs's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldKnow Labs (NYSEAMERICAN:KNW) Shares Up 3.8% – Should You Buy?Know Labs stock rose 3.8% during Thursday trading to $2.1390 per share, with approximately 612,050 shares traded, significantly below the stock's average daily volume of 4.4 million shares. The article provides background on Know Labs as a life sciences company developing non-invasive Bio-RFID technology for detecting biochemical markers like blood glucose, and notes that institutional investors including Cerity Partners LLC, Corient Private Wealth LLC, and Bard Financial Services Inc. acquired new positions in the company during recent quarters.openPR.comUnited States Non-Invasive Glucose Monitoring Devices Market Grows at 7.5% CAGR as Wearable Sensors and Needle-Free Diabetes Care Gain MomentumThe global non-invasive glucose monitoring devices market reached US$ 29.53 million in 2023 and is expected to reach US$ 60.71 million by 2033, growing at a CAGR of 7.5%, driven by rising global diabetes prevalence (affecting 537 million adults in 2023) and patient demand for pain-free needle-free monitoring technologies. Recent industry developments include Garmin's patent filing for non-invasive glycated haemoglobin estimation in smartwatches (June 2025), Afon Technology's launch of the world's first non-invasive real-time glucose sensor Glucowear (February 2025), and Know Labs' KnowU pursuing FDA clearance. North America leads the market with a valuation of US$ 13.2 million in 2024.BenzingaKnow Labs (KNW) Stock Jumps Again Monday On Bitcoin-Backed Acquisition MomentumKnow Labs Inc (NASDAQ:KNW) stock surged 104.2% on Monday, extending Friday's 200%+ rally, after announcing that Goldeneye 1995 LLC will acquire a controlling stake using 1,000 Bitcoin and cash. The acquisition values the stock at $0.335 per share, with former Ripple Chief Risk Officer Greg Kidd set to become CEO and chairman upon closing in Q3 2025, planning to hold Bitcoin as a treasury asset. Despite the valuation discount, investor enthusiasm has pushed the stock well above that level, reflecting optimism over the company's new Bitcoin-focused strategy.Stock TitanKnow Labs Latest Stock News & Market UpdatesKnow Labs Inc develops non-invasive diagnostic technologies using Bio-RFID and ChromaID systems to capture biomarker signatures. The company focuses on wearable devices like non-invasive blood glucose monitors, aiming to reduce patient discomfort. Its business model relies on selling medical devices and licensing technologies.BenzingaKnow Labs (KNW) Stock Soars Over 200% On Acquisition Deal, Bitcoin StrategyKnow Labs Inc (NASDAQ:KNW) shares surged 206.97% to $1.56 after announcing it will be acquired by Goldeneye 1995 LLC, an entity led by fintech investor and former Ripple Chief Risk Officer Greg Kidd, through a combination of 1,000 Bitcoin and cash to retire debt and fund operations. The deal values shares at $0.335, installs Kidd as CEO and chairman, and is expected to close in Q3 2025. A key component is a Bitcoin treasury strategy where Bitcoin holdings are expected to comprise 82% of the company's market cap at $105,000 per BTC, with the transaction unanimously approved by Know Labs' board.TradingViewKnow Labs shares more than triple as fintech investor plans Bitcoin-heavy takeoverGreg Kidd, through Goldeneye 1995 LLC, is acquiring a controlling interest in Know Labs, a medtech firm, using 1,000 Bitcoin. The Bitcoin will represent about 82% of the company's market cap after closing, and Kidd will become CEO. The deal is expected to close in Q3 2025.BioSpaceKnow Labs, Inc. Announces $300K Registered Direct OfferingKnow Labs, Inc. priced a registered direct offering of units at $0.24 per share, with gross proceeds of $300K before expenses. Each unit includes one share and one warrant exercisable at $0.24, expiring five years after issuance. The company plans to use proceeds for its non-invasive glucose monitor, pending FDA clearance.Business Wire BlogKnow Labs, Inc. Announces Receipt of Audit Opinion with Going Concern ExplanationKnow Labs, Inc. announced receipt of an audit opinion with a going concern explanation in its 10-K filed November 14, 2024. The opinion does not change the financial statements or the report. The company's first product, a non-invasive glucose monitor, requires FDA clearance before market introduction.Business Wire BlogKnow Labs, Inc. Announces $1.655 Million Public OfferingKnow Labs, Inc. closed a public offering on August 15, 2024, raising $1.655 million by selling 6,365,385 units to investors at $0.26 per unit. The company intends to utilize the net proceeds for product development, clinical studies, and working capital. Advisors Boustead Securities, LLC and The Benchmark Company, LLC facilitated the transaction.Business Wire BlogKnow Labs, Inc. Announces Pricing of $3.445 Million Public OfferingKnow Labs, Inc. announced the pricing of a $3.445 million public offering consisting of 13,250,000 units priced at $0.26 per unit, with closing expected around August 9, 2024. The company intends to utilize the net proceeds for product development, clinical studies, and general working capital. Underwriters The Benchmark Company, LLC and Boustead Securities, LLC are facilitating the transaction.